![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
0
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
The mdc-STM is an investigational three-month active injectable formulation of ivermectin using Medincell’s BEPO technology to fight malaria transmission.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: mdc-STM
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Unitaid
Deal Size: $6.0 million Upfront Cash: Undisclosed
Deal Type: Funding April 08, 2024
Details:
The SAIVE study was conducted to support mdc-TTG program, whose objective is to provide prevention of Covid-19 infection for weeks or months with a single injection of a long-acting formulation of ivermectin based on MedinCell’s proprietary technology, BEPO®.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
This non-exclusive licence agreement, will enable MPP to support the identification of suitable partners for the development and commercialisation of mdc-STM, an injectable formulation of ivermectin with a three-month action-duration.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: mdc-STM
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: The Medicines Patent Pool
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 13, 2022
Details:
Ivermectin is a Food and Drug Administration (FDA)-approved antiparasitic drug used to treat several neglected tropical diseases, including onchocerciasis, helminthiases, and scabies.
Lead Product(s): Ivermectin
Therapeutic Area: Dermatology Product Name: Ivermectin-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 04, 2022
Details:
Lyndra’s investigational long-acting oral biweekly ivermectin (LYN-163), enabled by Lyndra’s LYNX™ drug delivery platform, is being studied as a tool in the fight to eradicate malaria.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: LYN-163
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2022
Details:
The objective of MedinCell’s mdc-TTG program is to protect humans from Covid-19 and its variants with a long-acting injection of Ivermectin, SAIVE aims at validating the efficacy in prophylaxis against Covid-19 of administration of Ivermectin in oral daily form.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: mdc-TTG
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
Ivermectin is FDA-approved for prescription use in humans as an antiparasitic drug to treat conditions including intestinal strongyloidiasis and onchocerciasis or river blindness.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2021
Details:
The investigational product mdc-STM aims at reducing the transmission of the parasite responsible for Malaria, thanks to a killing effect on the vector mosquitoes when they bite treated people.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: mdc-STM
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2021
Details:
A single dose of 2.5 milligrams per kilogram of Ivectosol™ was effective at interfering with viral replication and driving viral clearance of the B.1.1.7 COVID-19 variant.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: Ivectosol
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2021
Details:
Ivermectin has already been administered as a once-daily treatment to hundreds of millions of patients worldwide. Its safety as a once-daily treatment has been demonstrated and documented.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2021
Details:
The EMA advice comes a month after Merck alerted against the ivermectin’s usage for Covid-19 as the results of the analysis did not support drug safety and efficacy.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 22, 2021
Details:
To support the patent examination request, the Company has provided the USPTO with new formulation analyses of different diluted concentrations of its Quicksol Ivermectin in solution, data that the company had fast-tracked for completion and validation by a third-party CRO.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 24, 2020
Details:
The ICON Study confirmed that the use of ivermectin is linked with a lower mortality in hospitalized COVID-19 patients despite being limited to an orally dosed tablet with poor bioavailability, which the company believes would be directly addressed with its discovery.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
A study by All India Institutes of Medical Sciences (AIIMS)-Bhubaneswar in the Indian state of Odisha found that two doses of potential drug ivermectin prophylaxis resulted in a 73% reduction in Covid-19 infection.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 05, 2020
Details:
Clinical trial of anti-androgen treatment Proxalutamide (GT0918) for the novel coronavirus disease (COVID-19) has reached the initial target of 381 patients enrolment on 25 October 2020. Also, it has demonstrated a positive trend.
Lead Product(s): Proxalutamide,Ivermectin,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: GT0918
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
The trial aims at validating the safety of continuous administration of Ivermectin in oral form Simultaneously, several long-acting injectable formulations based on MedinCell's BEPO® technology are being tested in vivo.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2020
Details:
The study on the effects of proxalutamide on COVID-19 has received national IRB approval and will be conducted in Brasilia, Brazil, in non-hospitalized patients with mildto-moderate COVID-19 disease.
Lead Product(s): Proxalutamide,Ivermectin,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Corpometria Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 22, 2020
Details:
ANDROCOV trial is for a Generic Anti-androgen as a Treatment For COVID-19 taking Dutasteride, Ivermectin, Azithromycin and Proxalutamide under combination.
Lead Product(s): Dutasteride,Ivermectin,Azithromycin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Applied Biology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 11, 2020
Details:
Company has commenced two pre-clinical trials designed to demonstrate the efficacy of its proprietary Quicksome™ technology in overcoming key absorption limitations of the oral drug Ivermectin and report pharmacokinetic results of Quicksome™ oral strip sublingual technology.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2020
Details:
Study reveal that antiparasitic drug Ivermectin can kill coronavirus in a laboratory setting in under 48 hours. A single treatment is able to effect ∼5000-fold reduction in 48h in cell culture.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
Details:
The grant aims to fund the formulation and preclinical activities of a 3-month acting injectable ivermectin to neutralize the transmission vector of Malaria.
Lead Product(s): Ivermectin
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Unitaid
Deal Size: $6.4 million Upfront Cash: Undisclosed
Deal Type: Funding March 25, 2020